Atterx
2 known investors
Atterx Biotherapeutics develops therapeutics to prevent and treat antibiotic-resistant bacterial infections, including drug candidates for Gram-negative infections (GN-4474) and catheter-associated urinary tract infections (C-1205). The company operates in the biotechnology and pharmaceutical sector focused on antimicrobial resistance.
Founders & leadership
JM
James MillarChief Executive Officer
Investors · 2
Frequently asked questions
- What does Atterx do?
- Atterx Biotherapeutics develops therapeutics to prevent and treat antibiotic-resistant bacterial infections, including drug candidates for Gram-negative infections (GN-4474) and catheter-associated urinary tract infections (C-1205). The company operates in the biotechnology and pharmaceutical sector focused on antimicrobial resistance.
- Who are Atterx's investors?
- Atterx's investors include Michigan Rise, Wisconsin Investment Partners.